[1]
|
Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma[J]. Expert Opin Biol Ther, 2019, 19(11):1143-1156. doi: 10.1080/14712598.2019.1641196
|
[2]
|
Ghosh A, Mailankody S, Giralt SA, et al. CAR T cell therapy for multiple myeloma:where are we now and where are we headed[J]? Leuk Lymphoma, 2018, 59(9):2056-2067. doi: 10.1080/10428194.2017.1393668
|
[3]
|
Morandi F, Horenstein AL, Costa F, et al. CD38:A target for immunotherapeutic approaches in multiple myeloma[J]. Front Immunol, 2018, 9:2722. doi: 10.3389/fimmu.2018.02722
|
[4]
|
Kriegsmann K, Dingeldein M, Cremer M, et al. Cell-based immunotherapy approaches for multiple myeloma[J]. Br J Cancer, 2019, 120(1):38-44. doi: 10.1038/s41416-018-0346-9
|
[5]
|
Rosenblatt J, Avigan D. Cellular Immunotherapy for multiple myeloma[J]. Cancer J, 2019, 25(1):38-44. doi: 10.1097/PPO.0000000000000356
|
[6]
|
Wu C, Zhang L, Brockman QR, et al. Chimeric antigen receptor T cell therapies for multiple myeloma[J]. J Hematol Oncol, 2019, 12(1):120. doi: 10.1186/s13045-019-0823-5
|
[7]
|
Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma[J]. Cancer, 2019, 125(14):2364-2382. doi: 10.1002/cncr.32065
|
[8]
|
Giuliani N, Malavasi F. Editorial:immunotherapy in multiple myeloma[J]. Front Immunol, 2019, 10:1945. doi: 10.3389/fimmu.2019.01945
|
[9]
|
Tamura H, Ishibashi M, Sunakawa M, et al. Immunotherapy for multiple myeloma[J]. Cancers (Basel), 2019, 11(12):91.
|
[10]
|
Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma:novel agents, antibodies, immunotherapies and beyond[J]. Leukemia, 2018, 32(2):252-262. doi: 10.1038/leu.2017.329
|
[11]
|
Giuliani N, Accardi F, Marchica V, et al. Novel targets for the treatment of relapsing multiple myeloma[J]. Expert Rev Hematol, 2019, 12(7):481-496. doi: 10.1080/17474086.2019.1624158
|
[12]
|
Fouquet G, Bories C, Guidez S, et al. Pomalidomide for multiple myeloma[J]. Expert Rev Hematol, 2014, 7(6):719-731. doi: 10.1586/17474086.2014.966074
|
[13]
|
Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003):a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2013, 14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2
|
[14]
|
Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma[J]. Blood, 2017, 130(8):974-981. doi: 10.1182/blood-2017-05-785246
|
[15]
|
Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma[J]. N Engl J Med, 2018, 379(19):1811-1822. doi: 10.1056/NEJMoa1805762
|
[16]
|
Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183):a randomised, openlabel, phase 3 trial[J]. Lancet Haematol, 2019, 6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3
|
[17]
|
Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma[J]. Blood, 2017, 130(10):1189-1197. doi: 10.1182/blood-2017-03-775122
|
[18]
|
Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM):a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4
|
[19]
|
Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR):a randomised, phase 3, open-label, multicentre study[J]. Lancet Oncol, 2016, 17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7
|
[20]
|
Dimopoulos M, Siegel D, White DJ, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure:a subgroup analysis of ENDEAVOR[J]. Blood, 2019, 133(2):147-155. doi: 10.1182/blood-2018-06-860015
|
[21]
|
Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib-lenalidomidedexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment[J]. Blood Cancer J, 2017, 7(4):e554. doi: 10.1038/bcj.2017.31
|
[22]
|
Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-oflife results from the open-label, randomized, phase Ⅲ ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma[J]. J Clin Oncol, 2016, 34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648
|
[23]
|
Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma[J]. J Clin Oncol, 2018, 36(8):728-734. doi: 10.1200/JCO.2017.76.5032
|
[24]
|
Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma[J]. Blood, 2019, 133(18):1953-1963. doi: 10.1182/blood-2018-09-874396
|
[25]
|
Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma[J]. N Engl J Med, 2018, 378(6):518-528. doi: 10.1056/NEJMoa1714678
|
[26]
|
Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma[J]. N Engl J Med, 2019, 380(22):2104-2115. doi: 10.1056/NEJMoa1817249
|
[27]
|
Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE):a randomised, open-label, phase 3 trial[J]. Lancet, 2020, 395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3
|
[28]
|
Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA):a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1
|
[29]
|
Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma:the GRIFFIN trial[J]. Blood, 2020, 136(8):936-945. doi: 10.1182/blood.2020005288
|
[30]
|
Caraccio C, Krishna S, Phillips DJ, et al. Bispecific antibodies for multiple myeloma:a review of targets, drugs, clinical trials, and future directions[J]. Front Immunol, 2020.[Epub ahead of print].
|
[31]
|
Giuliani N, Accardi F, Marchica V, et al. Novel targets for the treatment of relapsing multiple myeloma[J]. Expert Rev Hematol, 2019, 12(7):481-496. doi: 10.1080/17474086.2019.1624158
|
[32]
|
Panowski SH, Kuo TC, Zhang Y, et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma[J]. Mol Cancer Ther, 2019, 18(11):2008-2020. doi: 10.1158/1535-7163.MCT-19-0007
|
[33]
|
Zuch DZC, Fajardo F, Zhong W, et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release[J]. Clin Cancer Res, 2019, 25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752
|
[34]
|
Bruins W, Zweegman S, Mutis T, et al. Targeted therapy with immunoconjugates for multiple myeloma[J]. Front Immunol, 2020.[Epub ahead of print].
|
[35]
|
Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159):a dose escalation and expansion phase 1 trial[J]. Lancet Oncol, 2018, 19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X
|
[36]
|
Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma[J]. Blood, 2017, 130(24):2594-2602. doi: 10.1182/blood-2017-06-793869
|
[37]
|
Jhaveri KD, Wanchoo R. Selinexor for refractory multiple myeloma[J]. N Engl J Med, 2019, 381(20):1977. doi: 10.1056/NEJMc1912625
|
[38]
|
Stirrups R. Selinexor-dexamethasone for refractory multiple myeloma[J]. Lancet Oncol, 2019, 20(10):e560. doi: 10.1016/S1470-2045(19)30566-2
|
[39]
|
Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma[J]. Br J Haematol, 2020, 189(6):1136-1140. doi: 10.1111/bjh.16454
|
[40]
|
Vaxman I, Sidiqi MH, Gertz M. Venetoclax for the treatment of multiple myeloma[J]. Expert Rev Hematol, 2018, 11(12):915-920. doi: 10.1080/17474086.2018.1548931
|